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Transforming Growth Factor-b1 (TGFb1), -2, and -3 Gene
Expression in Isolated Prostatic Epithelial and Stromal
Cells: Epidermal Growth Factor and TGFb Interactions*
NAOKI ITOH†, URVASHI PATEL, ANDREA S. CUPP,

AND

MICHAEL K. SKINNER

Center for Reproductive Biology, Department of Genetics and Cell Biology, Washington State
University, Pullman, Washington 99164-4231
ABSTRACT
Growth factors are postulated to mediate stromal-epithelial interactions in the prostate to maintain normal tissue physiology. Transforming growth factor-b (TGFb) has been shown to influence the
prostate and probably mediate stromal-epithelial interactions.
TGFb1 messenger RNA (mRNA) expression is stimulated after castration and can be suppressed by in vivo treatment with androgens.
The hypothesis tested is that TGFb is regulated not only by androgen,
but also by a network of locally produced growth factors that influence
prostatic growth and differentiation. Epithelial and stromal cells from
20-day-old rat ventral prostate were isolated and used to test this
hypothesis. The expression of mRNA for TGFb1, -2, and -3 was analyzed by a quantitative RT-PCR procedure. Observations from this
assay demonstrate that both epithelial and stromal cells express the
mRNA for TGFb1, -2, and -3. TGFb1 mRNA expression was constant
during development of the prostate. TGFb2 mRNA expression was
elevated at birth, then declined and elevated again at 100 days of age.
TGFb3 mRNA expression was high during puberty and young adult
ages then declined at 100 days of age. TGFb2 and TGFb3 expression
are inversely related during prostate development. After castration of
60-day-old rats, both TGFb1 and TGFb2 mRNA were enhanced. Interestingly, TGFb3 mRNA was significantly suppressed after castra-

A

NDROGENS are essential for the growth, development, and function of the prostate gland (1). The actions of androgen on the prostate appear to be in part mediated through stromal-epithelial interactions (2– 4). Several
growth factors that are produced by stromal cells in response
to androgen can influence epithelial cells of the prostate (5).
Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), and insulinlike growth factors I and II can all stimulate growth of prostatic epithelial cells (6 – 8). In contrast, transforming growth
factor-b (TGFb) has been shown to have inhibitory effects on
prostatic stromal cells and epithelial cells (6). Androgens
have been shown to regulate growth factor gene expression
in the prostate (9 –12). In addition, growth factors influence
growth factor expression. For example, TGFb1 enhances
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tion. Epidermal growth factor (EGF) stimulated TGFb1 mRNA expression in stromal cells (6-fold increase), whereas keratinocyte
growth factor stimulated TGFb2 mRNA in epithelial cells. TGFb
inhibited both testosterone- and EGF-stimulated prostatic stromal
and epithelial cell growth. EGF and TGFb also inhibited prostatic
ductal morphogenesis and growth in organ culture. Immunocytochemical localization of TGFb in 20-day-old prostate demonstrated
predominately stromal localization of the protein.
These results indicate that the isoforms of TGFb2 and TGFb3 are
differentially regulated during prostate development, suggesting distinct regulatory mechanisms. Testosterone did not affect TGFb expression in cultured prostatic cells. These observations suggest that
the in vivo effects of castration on TGFbs are regulated indirectly
through a complex network of growth factors, not simply by direct
androgen depletion. The ability of EGF to inhibit prostatic ductal
morphogenesis and growth in organ culture is postulated to be in part
mediated by the increase in TGFb1 expression. In summary, a network of growth factor-mediated stromal-epithelial interactions is
needed to maintain prostate growth and development. TGFb is postulated to have an important role in this process. (Endocrinology 139:
1378 –1388, 1998)

bFGF expression in cultured human prostate stromal cells
(13, 14). The hypothesis was developed that a network of
locally produced growth factors is required for prostate
growth and differentiation.
Three isoforms of TGFb (TGFb1, -2, and -3) have been
identified in mammals, and their actions on cultured cells are
similar in activity and potency (15). The biological actions of
TGFb are numerous and include control of cell proliferation,
adhesion, and differentiation (15). TGFbs generally have
growth inhibitory activity on epithelial, neuronal, and lymphoid cells. TGFb activates the synthesis of extracellular
matrix components (16). Recently, it was found that inhibition of cyclin-dependent kinases by TGFb results in growth
arrest of cells in the G1 phase of the cell cycle (17, 18). TGFb
has dramatic effects on the prostate (19, 20) through inhibiting the growth of both epithelial and stromal cells (13, 21,
22). These observations suggest that an alteration of TGFb
expression may cause an imbalance in growth regulation of
stromal and epithelial cells in the prostate. For example,
TGFb may have a role in prostate cancer (23, 24). After
ablation of androgen by castration, the expression of TGFb1
in the prostate increases and can be suppressed by in vivo
treatment with androgen (9, 25). This observation suggests
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that the expression of TGFb may be regulated by androgen
in normal prostate. TGFb has been identified in stromal cells
in rat ventral prostate and in an epithelial cell line derived
from rat dorsal prostate (26, 27). Cultured human prostatic
stromal and epithelial cells have been shown to express
TGFb1, -2, and -3 by RT-PCR (28). The developmental and
hormonal regulation of TGFb1, -2, and -3 has not been thoroughly investigated.
The current study investigates the development and hormonal regulation of TGFb1, -2, and -3 expression. Isolated
epithelial cells and stromal cells from rat ventral prostate
were used in the in vitro experiments to investigate the actions of testosterone and growth factors.
Materials and Methods
Animals
Male Sprague-Dawley rats were purchased from Bantin-Kingman
(Kent, WA). Animals of a variety of ages, including 1-, 20-, 60-, and
100-day-old rats, were used for the study of prostate development. Some
of the 60-day-old rats were castrated under avertin anesthesia, which
consists of 25 g tribromoethanol in 15.5 ml tertiary amyl alcohol. The
prostate glands were removed 3 days after castration. Culture of both
prostatic epithelial and stromal cells used 20-day-old rat prostates. Organ culture of ventral prostates used 0-day-old rat prostates. All animal
procedures were approved by the university animal care committee.
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human fibroblast) cell lines. After primary antibody incubations, the
cells were rinsed three times in TBS and incubated with either goat
antirabbit or antimouse IgG horseradish peroxidase-conjugated secondary antibody (Sigma). Visualization was achieved using 50 mm Tris (pH
7.6) containing 0.6% diaminobenzine and 0.03% H2O2 for 10 min at 20
C. The cells were then counterstained in hematoxylin and mounted on
slides using an aqueous mounting solution. Stained cells were counted
in four separate areas of the slide using cells from five different
experiments.
Ventral prostate sections were obtained from 20-day-old SpragueDawley rats. Tissue specimens were immediately fixed in Bouin’s solution for 3– 6 h. Tissue was cut into 5-mm thick sections, deparaffinized,
rehydrated, and treated with an aqueous solution of 3.0% H2O2 to
quench endogenous peroxidase. After several washes in TBS buffer,
sections were incubated in TBS containing 1% BSA for 2 h at 37 C to
reduce nonspecific staining. After rinsing three times in TBS, a sheep
antirat pan TGFb antibody (East Acres Biological, South Bridge, MA)
was added at a 1:500 dilution and incubated overnight at 37 C followed
by 2 h at 4 C. For controls, a nonimmune sheep IgG was used at a similar
dilution. After three rinses in TBS, the primary antibody was detected
with antisheep biotinylated secondary antibody, and the biotin was
detected with an avidin-biotin-peroxidase kit (ABC-Elite, Vector Laboratories, Burlingame, CA). Diaminobenzidine tetrachloride was used as
a chromagen, and serial sections were lightly counterstained with
hematoxylin.

Culture of ventral prostate cells
The isolated cell cultures used 20-day-old Sprague-Dawley rats; these
animals were killed, and ventral prostates were removed. Tissue was
incubated with Hanks’ Balanced Salt Solution (Life Technologies, Gaithersburg, MD) containing 675 U collagenase activity/ml type II collagenase (Sigma Chemical Co., St. Louis, MO) and 0.04% deoxyribonuclease
I (Sigma) at 37 C for 4 h. After incubation, tissue was separated by
centrifugation. The mixture was spun at 30 3 g for 4 min to pellet the
epithelial cells. The remaining supernatant was centrifuged at 190 3 g
for 6 min to pellet the stromal cells. Both pellets were resuspended and
spun at 30 3 g for 4 min. The supernatant from stromal cells was
removed and repelleted at 190 3 g for 6 min. These were then subsequently placed in 10% bovine calf serum F-12 medium in six-well culture
plates (Nunclon, Roskilde, Denmark) at 3 3 105 cells/well. After 24 h,
the cells were washed in serum-free F-12 medium and incubated for 24 h.
On day 3 of culture, the cells were maintained in serum-free conditions
and incubated with or without the following treatments: from 1026-1029
m testosterone (Sigma), 100 ng/ml EGF (Life Technologies), 25 ng/ml
KGF (Life Technologies), 10 ng/ml human recombinant TGFb1 (Life
Technologies), 10% bovine calf serum (HyClone, Logan, UT), and a
combination of TGFb1 and testosterone (1027 m), EGF, or 10% bovine
calf serum. The treatments were administered for a period of 72 h. On
the sixth day of culture, the medium was removed and stored for
measurement of acid phosphatase at 220 C, and cells were harvested for
RNA extraction.

Cell purity assay and immunocytochemistry
The purity of ventral prostate stromal and epithelial cells in culture
was analyzed by immunohistochemical methods. Isolated stromal or
epithelial cells were plated in four-well culture plates at 3 3 105 cells/
well on Thermonox coverslips (Nunc, Inc., Naperville, IL). Two days
postplating, cells were fixed in 100% methanol for 5 min, then washed
in decreasing ethanol conditions and equilibrated in Tris-buffered saline
(TBS; pH 7.4). Before antibody staining, the cells were treated with H2O2
to quench endogenous peroxidases and then incubated in TBS containing 1% BSA and 0.5% normal serum for 1 h at 20 C. After rinsing three
times in TBS, cells were incubated for 2 h at 37 C with either rabbit
polyclonal antikeratin (Dako Corp., Carpenteria, CA) or a monoclonal
antivimentin (Sigma) antibody at dilutions of 1:250 and 1:300, respectively. Negative controls had no primary antiserum added, and positive
controls used epithelial (MCF-10A, human breast) and stromal (SS-140,

FIG. 1. Relationship between cycle numbers and optimal density
as PCR products of TGFb1, -b2, and -b3 and cyclophilin. Values are
expressed as the mean 6 SEM (n 5 3). Linearity between cycle
numbers and PCR products are shown in each growth factor as
follows: TGFb1; 25–35; TGFb2; 27– 40; TGFb3; 30 – 40; and cyclophilin; 15–30.
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RNA preparation
Total RNA was obtained using Tri Reagent (Sigma). Briefly, tissue or
cells were lysed in Tri Reagent (1 ml/50 –100 mg tissue or 1 ml/10 cm2
of culture plate). After adding 0.2 ml chloroform/ml Tri Reagent, the
mixture was centrifuged at 12,000 3 g for 15 min at 4 C, the colorless
upper aqueous phase was transferred to a fresh tube, and 0.5 ml isopropanol/ml Tri Reagent was added to pellet the RNA. The mixture was
centrifuged at 12,000 3 g for 10 min at 4 C. The RNA pellet was washed
with 75% ethanol and resuspended in diethylpyrocarbonate (DEPC)treated H2O. RNA was stored at 280 C until analysis.
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plasmid were 1 ng/ml and 10 ng/ml, respectively. This concentration of
Bluescript plasmid was included in all samples and standards.

Quantitative PCR assay
As a standard for the assay, PCR products of TGFb1, -2, and -3 and
cyclophilin amplified by each specific primer were subcloned into Blue-

RT
Complementary DNA (cDNA) was synthesized in a total 20-ml volume containing 1 mg total RNA, 0.05 mm of specific 39-primers (TGFb1,
59-GGG GTG GCC ATG AGG AGC AGG-39; TGFb2, 59-GCG CTG GGT
GGG AGA TGT TAA-39; TGFb3, 59-CCT TTG AAT TTG ATC TCC A-39;
cyclophilin, 59-ATT TGC CAT GGA CAA GAT GCC-39), 4 ml 5 3 first
strand PCR buffer (Life Technologies), 10 mm dithiothreitol (Life Technologies), 0.125 mm deoxy-NTPs, 100 U Moloney murine leukemia virus
transcriptase (Life Technologies), 20 U ribonuclease inhibitor (Promega,
Madison, WI), and DEPC-H2O. Initially, RNA was denatured and annealed in the presence of each primer and DEPC-H2O at 65 C for 15 min.
The tube was placed on ice for 5 min. The other reagents were added
to the tube and incubated at 42 C for 2 h. To decrease the high background signal, a higher RT reaction temperature (42 C) was used (29).
The mixture was incubated at 95 C for 5 min to inactivate Moloney
murine leukemia virus transcriptase. The mixture was diluted by UVtreated H2O containing Bluescript plasmid DNA (Stratagene, La Jolla,
CA) as carrier DNA. The final concentrations of cDNA and Bluescript

FIG. 3. Expression of mRNA of TGFb1, -b2, and -b3 in both epithelial
cells and stromal cells. Fresh cells that are separated into epithelium
and stroma from 20-day-old rat ventral prostate and cells after 6-day
culture are analyzed. Values are normalized with cyclophilin and are
expressed as the mean 6 SEM (n 5 4).

FIG. 2. Diluted curve of both plasmid DNA (standard) and total RNA in TGFb1, -b2, and -b3 and cyclophilin. Values are expressed as the mean 6
SEM (n 5 2). Parallel relationships in PCR products between plasmid DNA and total RNA are shown.
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script plasmid (Stratagene). Each subclone was sequenced in both directions and confirmed to be rat TGFb1, -2, and -3 and cyclophilin. The
size and base pair alignment of the PCR product generated were as
follows: 200 bp size from 1003–1203 bp alignment on the coding sequence (accession no. 52498; TGFb1), 194 bp size from 355–549 bp
alignment on the coding sequence (TGFb2), 288 bp size from 865-1153
bp alignment on the coding sequence (accession no. 403491; TGFb3), and
105 bp size from 244 –348 bp alignment on the coding sequence (accession no. M19533; cyclophilin). Plasmid DNA containing TGFb subclones
was used to generate standard curves ranging from 0.1 fg/ml to 1.0
pg/ml, and for cyclophilin from 10 fg/ml to 100 pg/ml. PCR was performed on a Perkin-Elmer GeneAmp PCR System 9600 (Perkin-Elmer,
Branchburg, NJ) and was carried out in a total 25-ml reaction volume
containing 5 ml plasmid DNA or RT reaction, 0.4 mm 39-primer as shown
above, 0.4 mm 59-primer (TGFb1, 59-TCG ATT TTG ACG TCA CTG GAG
TTG T-39; TGFb2, 59-CCG CCC ACT TTC TAC AGA CCC-39; TGFb3,
59-TGC CCA ACC CGA GCT CTA AGC G-39; cyclophilin, 59-ACA CGC
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CAT AAT GGC ACT GG-39), 2.5 ml 10 3 GeneAmp PCR buffer (containing 1.5 mm MgCl2; Perkin-Elmer), 25 mm deoxy-NTPs, 0.5 U Taq
DNA polymerase (Perkin-Elmer), and 1 mCi [a-32P]deoxy-CTP (Amersham Life Science, Arlington Heights, IL).
The TGFb1 reaction cycle sequence comprised 5 min at 95 C, followed
by 30 cycles of 1 min at 95 C, 1 min at 60 C, and 2 min at 72 C. The
cyclophilin reaction cycle sequence comprised 5 min at 95%, followed
by 25 cycles of 1 min at 95 C, 1 min at 60 C, and 2 min at 72 C. The TGFb2
reaction cycle sequence comprised 5 min at 95 C, followed by 33 cycles
of 1 min at 95 C, 2 min at 60 C, and 3 min at 72 C. The TGFb3 reaction
cycle sequence comprised 5 min at 95 C, followed by 35 cycles of 1 min
at 95 C, 2 min at 55 C, and 3 min at 72 C. All reactions had a final extension
for 10 min at 72 C.
After PCR, the products were electrophoretically separated on a 6%
acrylamide gel. The gel was then dried and analyzed on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) quantitatively. Each
gene was assayed in separate PCR reactions from the same RT samples.

FIG. 4. Changes in the relative expression of TGFb1, -b2, and -b3 during development of rat ventral prostate. Values are normalized with cyclophilin and
compared with those of 20-day-old rats
as relative expression and presented as
the mean 6 SEM (n 5 3–5). Statistical
difference is indicated by different letter superscripts (P , 0.05).

FIG. 5. Relative expression of TGFb1 (A), TGFb2 (B), and TGFb3 (C) in cultured rat ventral prostate with or without treatment. Values are
normalized with cyclophilin and are presented as the relative expression compared with control cultures. Values were expressed as the mean 6
SEM (n 5 4 –12). Statistical difference is indicated by different letter superscripts (P , 0.05).
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Equivalent steady state messenger RNA (mRNA) levels for each gene
were determined by comparing each sample to the appropriate standard
curve. TGFb1, -2, and -3 were normalized for cyclophilin. For each assay,
all samples were simultaneously measured in duplicate with intraassay
variabilities of 7.5% (TGFb1), 9.4% (TGFb2), 9.9% (TGFb3), and 9.2%
(cyclophilin).

Cell growth assay
Cell growth was analyzed by examining [3H]thymidine incorporation
into newly synthesized DNA. Stromal and epithelial cells were placed
at subconfluent densities (,1 million cells/cm2) in 0.5 ml DMEM containing 0.1% calf serum. The low serum level does not stimulate growth
and is required for progression factors (i.e. insulin-like growth factor) for
the S phase of the cell cycle to detect the growth factor response. After
48 –72 h of culture, the cells were treated with various agents for 24 h.
After the 24-h treatment, 0.5 ml DMEM containing 2 mCi [3H]thymidine
was added to each well, and the cells were incubated for 4 h at 37 C
before sonication. The quantity of [3H]thymidine incorporated into
DNA was determined as previously described (30). Data were normalized to total DNA per well using an ethidium bromide procedure,
described previously (31). Under these subconfluent culture conditions,
approximately 0.5–1.5 mg DNA were detected per well. [3H]Thymidine
incorporation was generally greater than 2 3 103 cpm/mg DNA.

Organ culture of rat ventral prostate
Ventral prostates were removed from 0-day-old rats and cultured in
a drop of medium on a Millicell CM filter (Millipore, Bedford, MA)
floating on the surface of 0.5–1.0 ml CMRL 1066 medium (Life Technologies, Gaithersburg, MD) supplemented with penicillin-streptomycin, insulin (10 mg/ml), and transferrin (10 mg/ml) with or without
treatments. The cultures were performed in a four-well Nunclon surface
dish (32). These plates were placed in the incubator at 37 C in an
atmosphere of 5% CO2 and 95% air. The tissues were cultured for 6 days.
Treatments were testosterone (Sigma; 1027 m), EGF (Life Technologies;
100 ng/ml), TGFb1 (Life Technologies; 10 ng/ml), and a combination of
testosterone and EGF or a combination of testosterone and TGFb1.
Images of the prostates were captured with an image analysis system
(Pixera, Pixera Corp., Los Gatos, CA). At the end of the culture, the
organs were fixed for histology. The analysis and quantitation of ductal
branching morphogenesis were previously described (32).

Statistical analysis
All data were analyzed by a JMP 3.1 statistical analysis program (SAS
Institute, Cary, NC). All values are expressed as the mean 6 sem.
Statistical analysis was performed using one-way ANOVA. Significant
differences were determined using the Dunnett’s test for comparison to
controls and using the Tukey-Kramer honestly significant difference test
for multiple comparisons. Statistical difference was confirmed at P ,
0.05.

Results
Characterization of the quantitative RT-PCR (QRT-PCR)
for TGFb1, -2, and -3 and cyclophilin

Preliminary studies were performed to establish a reproducible and accurate QRT-PCR procedure. The linearity of
generating a PCR product relative to cycle number was determined (33). The PCR product for TGFb1 increased at 25
cycles and reached a plateau at 36 cycles. Thirty cycles was
selected to be an appropriate cycle number for QRT-PCR
(Fig. 1A). The TGFb2 PCR product continued to be amplified
at 42 cycles. For TGFb2, 33 cycles was midpoint on the linear
amplification of the PCR product and was selected for QRTPCR (Fig. 1A). TGFb3 product started to increase after 30
cycles and reached a plateau level at 40. Thirty-five cycles
was determined appropriate to use for TGFb3 (Fig. 1B). For

FIG. 6. The [3H]thymidine incorporation growth assay on cultured
rat ventral prostate cells. Values are expressed as the mean 6 SEM
(n 5 3; control 5 1). Statistical difference is indicated by different
letter superscripts (P , 0.05).

cyclophilin, 25 cycles was determined to be the appropriate
cycle number (Fig. 1B).
Another aspect of the QRT-PCR procedure involves a comparison of standard DNA with unknown samples for parallel
displacement. Plasmid DNA with subcloned PCR product
and cDNA produced from unknown RNA samples were run
in parallel. PCR products of diluted plasmid DNA and diluted unknown cDNA were compared. These two curves
were parallel with each growth factor, indicating that the
QRT-PCR assay could be used to quantitate mRNA levels
(Fig. 2, A–D). The small error shown in each of the data points
demonstrates minimal variability in the assay (Figs. 1 and 2).
Comparison of growth factor expression in fresh and
cultured stromal and epithelial cells

Analysis of TGFb1, -2, and -3 mRNA expression in both
stromal and epithelial cells of rat ventral prostate was determined. The differences in the expression pattern of these
products between freshly isolated ventral prostate cells and
cultured cells was investigated. In freshly isolated cells from
20-day-old rat prostate, TGFb expression normalized by cyclophilin ranged from 0.3– 6 3 1023 fg TGFb/fg cyclophilin
(Fig. 3). Expression of TGFb1 and -2 was higher in stromal

TGFb-MEDIATED PROSTATIC STROMAL-EPITHELIAL INTERACTIONS
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FIG. 7. Ventral prostate after 6 days of
treatment with testosterone (1027 M),
EGF (100 ng/ml), TGFb1 (10 ng/ml), or
their combination in organ culture.
These ventral prostates were removed
from 0-day-old Sprague-Dawley rats.
Data are representative of three different experiments performedin replicate.

cells than in epithelial cells. TGFb3 expression in epithelial
cells was the same as that in stromal cells. In cultured samples derived from 20-day-old rat ventral prostate, TGFb1, -2,
and -3 showed higher expression than fresh samples and
ranged from 7–700 3 1023 fg TGFb/fg cyclophilin. Contrary
to that in fresh samples, expression in epithelial cells in
cultured samples was higher than that in stromal cells. In
both epithelial and stromal cells, TGFb1 had the lowest level
of expression, and TGFb3 had the highest level of expression
(Fig. 3).
Developmental regulation of TGFb expression in
rat prostate

To investigate the changes in TGFb1, -2, and -3 expression
during rat development from the neonatal period (1-day-old)

to adulthood (100-day-old), ventral prostates were removed
from rats aged 1, 20, 60, and 100 days, and the mRNA expression of TGFb was measured by QRT-PCR. The effects of
androgen depletion on TGFb1, -2, and -3 expression were
analyzed by castration of 60-day-old rats. The expression of
TGFb isoforms was normalized by cyclophilin expression,
and relative expression was compared with that in 20-dayold rats. TGFb1 expression did not vary during development
(Fig. 4). After castration of 60-day-old rats, TGFb1 significantly increased to 5-fold that in 60-day-old rats. During the
neonatal period, TGFb2 expression was elevated, then decreased in pubertal and early adult periods (60 days of age)
and was elevated in adult rats (100 days old). After castration, TGFb2 was increased 4-fold, but remained lower than
that in 100-day-old rats. In contrast to TGFb2, TGFb3 ex-
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pression was very low in the 1- and 100-day-old prostates
and was elevated during the pubertal and early adult periods
(60 days of age). After castration, TGFb3 expression was
significantly suppressed from that in 60-day-old rats. Interestingly, TGFb3 expression was inversely related to TGFb2
expression (Fig. 4).
Hormonal regulation of TGFb expression in cultured
prostate cells

The effects of testosterone and growth factors on TGFb1,
-2, and -3 expression were investigated in stromal and epithelial cells derived from ventral prostate of 20-day-old rats.
EGF and KGF were used as stimulatory growth factors, and
human recombinant TGFb1 was used as an inhibitory
growth factor. TGFb1 was combined with testosterone or
EGF to study potential suppressive effects. All values were
normalized with cyclophilin and expressed as relative expression compared with that in control cultures.
Analysis of cell purity indicated that isolated epithelial
cells showed 93.2 6 1.2% (mean 6 sem; n 5 5) keratinpositive cells and less than 3% vimentin-positive cells. Isolated stromal cells showed 86.0 6 3.5% (mean 6 sem; n 5 5)
vimentin-positive and less than 5% keratin-positive cells.
These results demonstrate that cell purity in both isolated
stromal and epithelial cells were appropriate for data
interpretation.
EGF significantly stimulated (6-fold) TGFb1 expression in
stromal cells (Fig. 5A) and significantly stimulated the expression of TGFb1 in epithelial cells at a reduced level (2.5fold) compared to that in stromal cells. This effect was not
significantly different compared with that of other treatments, but was different from the control. TGFb1 had no
effect on the expression of TGFb1 in either stromal or epithelial cells. The effects of EGF on TGFb1 expression were not
influenced by exogenous administration of TGFb1 in either
cell type. Neither testosterone nor KGF had any effect on
TGFb1 expression in either cell type (Fig. 5A).
In stromal cells, the expression of TGFb2 was elevated to
approximately 1.5-fold by each treatment; however, these
effects were not statistically significant (Fig. 5B). In epithelial
cells, only KGF significantly stimulated (2.8-fold) TGFb2 expression. TGFb1 alone did stimulate TGFb2 expression, but
this stimulation was not statistically different from that in
control cultures (Fig. 5B). Results indicate that prostate stromal cells were not influenced by any treatment, and epithelial cells were only influenced by KGF with regard to TGFb2
expression.
No treatment affected TGFb3 expression in either stromal
or epithelial cells (Fig. 5C). Although small effects were observed with testosterone and TGFb1, these were not statistically different from those in control cultures.
Combined observations indicate that EGF regulates
TGFb1 expression by stromal and epithelial cells, KGF regulates TGFb2 expression by epithelial cells, and none of the
treatments used in the current study influences TGFb3 expression. Testosterone had no effect on TGFb1, TGFb2, or
TGFb3 in either cell type.
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Regulation of prostate cell growth

Stromal and epithelial cells from rat ventral prostates were
cultured to examine the effects of testosterone, EGF, KGF,
and TGFb1 on cell growth. A tritiated thymidine incorporation assay was performed using 10% bovine calf serum as
a positive control. Calf serum significantly stimulated (;4fold) DNA synthesis in both stromal and epithelial cells (Fig.
6). Testosterone and EGF stimulated (2.5- to 3-fold) DNA
synthesis in stromal and epithelial cells. KGF had a stimulatory effect on epithelial cells. TGFb had no direct effect on
DNA synthesis alone (Fig. 6). However, TGFb significantly
inhibited the growth effects of testosterone and EGF on stromal cells as well as the growth effects of testosterone on
epithelial cells. These results indicate that testosterone and
EGF can stimulate the growth of both stromal cells and
epithelial cells, whereas TGFb can inhibit these actions and
suppress growth. Although the growth response for testosterone was observed in less than 24 h, potential indirect
effects of testosterone mediated by other peptide growth
factors remain to be elucidated.
Regulation of ductal branching morphogenesis

To address the potential physiological function of TGFb,
an organ culture of 0-day-old rat prostate was used. Prostate
organ cultures can be used to analyze the effects of growth
factors on the whole organ, in which normal cell to cell
interactions are intact (32). Testosterone (1027 m) treatment
of prostate organ cultures promoted significant branching
morphogenesis compared with that in control cultures (Fig.
7). TGFb1 alone caused a slight reduction in the number of
branching ducts, but the number was similar to that in control cultures. However, TGFb1 completely inhibited the stimulatory effect of testosterone on prostatic ductal branching
morphogenesis (Figs. 7 and 8). EGF increased prostatic size;
however, ductal branching was significantly reduced (Figs.
7 and 8), and ducts were swollen, with an increase in surrounding stromal layers (Fig. 7). The histology of these organ
cultures is shown in Fig. 9 and demonstrates that EGF does
increase the stromal/epithelial cell ratio as well as shows the

FIG. 8. Number of branching ducts in 0-day-old rat ventral prostate
organ cultures, presented as the number of tips per mm2. Data were
obtained from images similar to those represented in Fig. 7. Data are
expressed as the mean 6 SEM (n 5 3). Different superscipt letters
indicate a statistical difference (P , 0.05).

TGFb-MEDIATED PROSTATIC STROMAL-EPITHELIAL INTERACTIONS

1385

FIG. 9. Histology of 0-day-old rat ventral prostate organ cultures after 6 days of culture. Data are presented at two magnifications, as indicated
with the treatments presented. Data are representative of three different experiments.
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epithelial cells are less organized into ductal structures. Testosterone promotes a polarized epithelial cell morphology,
whereas EGF promotes a more random proliferation of the
epithelium (Fig. 9). A combination of testosterone and EGF
caused enlargement of the prostate; however, this enlargement was not due to ductal formation and appears to be due
to stromal enlargement (Figs. 7 and 8). The degree of ductal
branching morphogenesis with testosterone and EGF was
increased over that with EGF alone (Fig. 8). The ratio of
stroma/epithelium was higher in the prostates treated with
EGF than in control cultures. Combined results indicate that
TGFb can inhibit the stimulatory effects of testosterone on
prostate morphogenesis. The ability of EGF to stimulate
TGFb may have a role in the inhibitory effects of EGF on
prostate ductal branching morphogenesis.
TGFb cellular localization

To address the in vivo localization of TGFb, a pan-TGFb
antibody that recognizes all three forms of TGFb was used
in immunocytochemistry of 20-day-old rat prostate sections.
TGFb protein was predominantly found in the stromal cell
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population, with only sparse staining in the epithelium (Fig.
10). TGFb staining was most intense in the stromal cells
adjacent to the epithelial cells. Although the mRNA for TGFb
was found in both cell types, the protein is primarily localized in stromal cells. Whether this is due to localization in the
extracellular environment of the stromal cells or is a reflection of production levels remains to be elucidated. Controls
with nonimmune IgG had no staining detected (Fig. 10).
Discussion

The current study was designed to investigate the developmental and hormonal regulation of TGFb expression in
the prostate. Previously, the three isoforms of TGFb were
shown to be present in normal prostate, benign prostatic
hyperplasia (BPH), and prostate cancer by Northern blot and
ribonuclease protection assays (26, 27, 34). Recently, TGFb1,
-2, and -3 mRNA were detected in stromal and epithelial cells
of normal human prostate and BPH by RT-PCR (28). For the
current study, a sensitive QRT-PCR procedure was developed to accurately investigate the regulation of TGFb expression. This QRT-PCR procedure was specific for the dif-

FIG. 10. Immunocytochemical localization of TGFb in 20-day-old rat prostate sections. Sections were incubated in the presence of nonimmune
antibody (B and D) or in the presence of a pan-TGFb antibody (A and C). Data are representative of three different experiments.
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ferent TGFb isoforms and used small amounts of tissue or
cells. All data obtained for TGFb were normalized for a
constitutively expressed gene, cyclophin. Cyclophilin expression did not change among the samples (data not shown)
and was corrected for variations in RNA amount and integrity. The QRT-PCR procedure developed was useful to investigate TGFb expression.
All three isoforms of TGFb, TGFb1, -2, and -3, were expressed in both stromal cells and epithelial cells from freshly
isolated cells and cultured cells. Freshly isolated prostatic
stromal cells have a higher level of TGFb expression than
epithelial cells. TGFb3 has the highest level of expression,
whereas TGFb1 has the lowest. The high levels of TGFb
mRNA in freshly isolated stromal cells correlated to the
immunocytochemical data, with TGFb staining predominantly in the stromal cells. However, epithelial cells did
express all isoforms of TGFb. During cell culture, the levels
of TGFb1, -2, and -3 increased in both cell types. Interestingly, the epithelial cells developed a higher level of expression than stromal cells in culture. This increase in expression
during culture may be due to the lack of regulatory agents
that suppress expression in normal in vivo tissue. Previously,
the type I and type II TGFb receptors (15) have been shown
to be expressed in the prostate (35). These observations suggest that both prostate stromal and epithelial cells have the
capacity to express TGFb1, -2, and -3, which may act as both
paracrine and autocrine factors to influence prostate
function.
The developmental regulation of TGFb1, -2, and -3 expression was investigated with neonatal day 0 rats, pubertal
day 20 rats, early adult day 60 rats, and adult day 100 rats.
TGFb1 expression (i.e. mRNA levels) remained constant during prostate development. TGFb2 expression was high during the neonatal and adult (100 day) periods and low during
the pubertal and early adult (60 day) periods. In contrast,
TGFb3 expression was low during the neonatal and adult
(100 day) periods and high during the pubertal and early
adult (60 day) periods. TGFb2 and TGFb3 expression appeared to be inversely related during prostate development.
Recently, the ratio of stromal to epithelial cells was measured
during prostate development and was constant throughout
(36). Therefore, the changes in TGFb1, -2, and -3 do not
appear to be due to alterations in the cell populations. Although the three isoforms of TGFb are highly homologous
and have similar biological activities, the developmental expression during prostate development appears distinct. The
inverse relation of TGFb2 and TGFb3 may reflect changes in
the regulation of prostate function and may be required to
coordinate local cell-cell interactions (37).
Androgens are postulated to be an essential factor to regulate TGFb expression in the prostate (9, 25). Both TGFb1 and
TGFb2 expression increased after castration. This supports
previous observations with TGFb1 (9, 10). Interestingly,
TGFb3 expression decreased after castration. Previously,
TGFb2 mRNA levels have been shown to be negatively correlated with androgen levels in both normal and malignant
prostate (34). The changes in TGFb expression during development cannot be directly correlated with serum androgen levels. The relationship of serum androgen levels and
TGFb expression remains to be elucidated. As discussed
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below, androgens have no effect on TGFb expression using
cultured prostate cells. Another factor to explain the changes
after castration is the alteration in the stromal/epithelial cell
populations (36). These observations suggest that the relationship of TGFb expression and androgen levels remains to
be elucidated and probably involves a combination of direct
and indirect actions of androgens.
Several interesting observations came from the analysis of
TGFb expression in cultured prostatic stromal and epithelial
cells. Both isolated cell populations were approximately 90 –
95% pure by an immunocytochemical analysis of the cell
populations. Androgens did not influence TGFb1, -2, or -3 in
either stromal cell or epithelial cell cultures. The concentrations of androgen used ranged from 1028-1026 m, with no
effect at any concentration (data not shown). This observation suggests that androgen may not have a dramatic direct
action on TGFb expression. TGFb3 expression was not influenced by any of the treatments used in the current study.
TGFb2 was also not affected in stromal cells by any treatment. KGF stimulated TGFb2 in epithelial cells. KGF has
been shown to mediate stromal-epithelial cell interactions in
the prostate and to influence prostate morphogenesis (3, 32,
36). The ability of KGF to influence TGFb2 expression in
prostate epithelium will probably have a role in the actions
of KGF on the prostate.
TGFb had no effect on TGFb1, -2, or -3 expression in either
stromal cells or epithelial cells. Previously, TGFb1 was found
to enhance bFGF expression in cultured human prostatic
stromal cells (13, 14). In rat kidney fibroblasts, TGFb has been
shown to stimulate TGFb expression (38). In the current
study, TGFb did not have a major regulatory role in the
control of TGFb expression.
Perhaps one of the more interesting observations made
was the effect of EGF on TGFb1 expression. EGF stimulated
the expression of TGFb1 by both prostatic stromal and epithelial cells. EGF has been shown to be a potent growth
stimulator of prostatic epithelium (39, 40). The observations
made in the current study suggest that EGF may also have
an important regulatory role. The actions of EGF on prostate
function and development discussed below will probably be
mediated in part by these effects on TGFb1 expression.
The effects of TGFb on cell growth were examined to
investigate the functional significance of TGFb in the prostate. Both EGF and testosterone dramatically stimulated
prostate stromal and epithelial cell growth. The potential
indirect actions of testosterone via peptide growth factors
need to be considered. TGFb inhibited the actions of testosterone and EGF on both cell types. This correlates with the
previously identified function of TGFb as a growth inhibitory substance. Previously, TGFb has been shown to inhibit
the growth of human prostate epithelial cells (21). An important function for TGFb will probably be as a growth
inhibitor in the prostate.
Another functional parameter of the prostate examined
was ductal branching morphogenesis in prostate organ cultures. This organ culture system has been developed to investigate morphogenesis of the prostate and actions of agents
such as androgens and KGF (36, 32). In the current study,
androgen was found to promote ductal branching morphogenesis, and TGFb was found to suppress the actions of
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androgens. This suggests that TGFb may have a role in regulating prostate morphogenesis. Interestingly, EGF also dramatically suppressed ductal branching morphogenesis. This was in
part due to a proliferation of stromal cells and a disorganization
of the epithelium. The ability of TGFb to suppress ductal
branching morphogenesis and inhibit EGF-stimulated growth
suggests that TGFb may have a role in this process. In support
of this proposal is the ability of EGF to stimulate TGFb1 expression. These observations suggest that TGFb will have a role
in prostate growth and morphogenesis. The actions of regulatory agents (e.g. EGF) on the prostate may be mediated indirectly through the production and action of TGFb.
The combined observations suggest that a network of locally
produced growth factors, such as KGF, EGF, and TGFb, will
coordinate prostate development and morphogenesis. This is
supported by observations in the current study regarding the
developmental and hormonal regulation of TGFb1, -2, and -3
expression in prostate stromal and epithelial cells. Regulatory
agents such as androgen probably involved both direct and
indirect actions mediated through this network of growth factors to control prostate function. The abnormal phenotypes in
prostate cancer and BPH will probably in part be due to the
inability of this network of regulatory agents and growth factors
to maintain normal prostate function. It is speculated that TGFb
will have a role in this process.
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